Europe Series A Weekly Funding Roundup (Mar 20-27, 2026): $36.5M Raised Across 2 Deals

Table of Contents

European Series A activity this week centered on two deals totaling $36.5M, both targeting the growing gap between AI agent ambitions and operational reality. A Paris-based healthtech startup pulled in $20M to deploy AI agents inside hospitals, while a Munich company raised $16.5M to solve the knowledge problem that causes most enterprise AI deployments to fail.

The common thread: both companies are building infrastructure layers rather than point solutions. They're betting that as organizations rush to adopt AI agents, the winners won't be the agent builders themselves but the companies that make agents actually work in messy, real-world environments. Index Ventures and DN Capital led the respective rounds, signaling investor appetite for European startups tackling AI deployment friction head-on.

1. Parallel Raises $20M For AI Hospital Agents

Deal Overview

• Stage: Series A
• Sector: Healthtech
• Geography: Paris, France
• Round size: $20M
• Total raised: ~$23.5M

Investor Profile

Index Ventures led the round, joined by existing backers Frst, Y Combinator, and Hexa. Index has a strong track record in European enterprise software and brings a deep network for international expansion. The angel roster includes Arthur Mensch, CEO of Mistral AI, along with Felix Blossier and Quentin de Metz from Pennylane. That mix of AI and European SaaS operators backing a healthtech play says something about where smart money sees AI agents gaining traction first.

Company and Leadership

Parallel was founded in 2024 by Paul Lafforgue and Chris Rydahl. Lafforgue is an École Polytechnique graduate who led search data at Meta and spent time at McKinsey. Rydahl brings direct healthcare distribution experience as the founder of Hublo, which grew into Europe's largest healthcare staffing platform. That combination of AI expertise and hospital-level trust capital is hard to replicate.

Problem and Opportunity

Administrative work consumes 30 to 40% of clinical staff time in European and US hospitals. Medical coding alone is a multi-billion dollar outsourcing industry. The root cause isn't a lack of software. It's that hospitals run on legacy systems with no APIs, making traditional software integration a 12 to 24 month process. Most health IT startups die in that integration gap before they can prove value.

Product and Technology

Parallel's AI agents skip the API problem entirely. Instead of integrating with hospital systems at the data layer, agents operate at the UI layer. They learn to navigate existing software the way a human would: reading screens, clicking through interfaces, entering data. This means deployment takes weeks, not years. The current focus is medical coding, where the agent reads clinical documentation, identifies the right ICD diagnosis codes, and enters them directly into billing systems. Each deployment generates labeled training data that improves accuracy over time.

Use of Proceeds and Vision

Funds will go toward expanding medical coding capabilities, international growth beyond France, building new AI agents for additional workflow categories, and hiring across engineering and go-to-market. The long-term play is a full administrative layer for hospital operations, starting with coding and expanding into billing, prior authorizations, and discharge documentation.

Market Context

The hospital staffing crisis is structural and getting worse. Clinical staff shortages aren't just a recruitment problem. They're an allocation problem. Doctors and nurses spend too many hours on paperwork. AI agents that work on top of legacy systems without requiring IT overhauls are well positioned to capture outsourcing spend that currently flows to BPO firms. Parallel is already live across multiple public and private hospitals in France, giving it real deployment data that desk-stage competitors lack.

Case Studies

Startups like yours already closed their rounds with us.

Founders across every stage and industry. Here's what it took.

• Raised $7.6M for Swiipr Technologies
• Raised $0.5M for Ap Tack
• Raised €0.5M for Ivent Pro

Read their stories →

2. Interloom Raises $16.5M For Enterprise AI Memory

Deal Overview

• Stage: Series A
• Sector: AI / Enterprise Software
• Geography: Munich, Germany
• Round size: $16.5M (€14.2M)
• Total raised: ~$19.5M

Investor Profile

DN Capital led the round with participation from Bek Ventures and returning investor Air Street Capital. DN Capital is one of Europe's most active enterprise-focused VCs with a strong DACH portfolio. Air Street Capital, which led the seed, specializes in AI-first companies. Their continued backing after seeing early traction with blue-chip enterprise customers is a meaningful signal.

Company and Leadership

Interloom was founded in 2024 by Fabian Jakobi, Miha Erzen, and Jaime Madrid. Jakobi previously founded Boxplot, which he sold to Hyperscience in 2021. Erzen serves as CTO. The team's prior experience building document intelligence products directly informs their approach to capturing tacit organizational knowledge.

Problem and Opportunity

About 70% of operational decisions inside enterprises are based on unwritten knowledge. How does this department handle a disputed invoice? What's the real escalation process when a vendor misses SLA? That information lives in people's heads, scattered emails, and call transcripts. When companies deploy general-purpose AI agents, those agents fail because they can't access this institutional memory. It's the single biggest reason enterprise AI pilots stall.

Product and Technology

Interloom ingests millions of operational records, from support tickets and emails to call transcripts and case histories, and constructs what they call a Context Graph. Unlike RAG solutions that pull from static documents, the Context Graph maps how problems actually get resolved in real workflows. It encodes what happened, not what was written down. Their newest product, a "Chief of Staff" agent, sits on top of this graph to help organizations roll out AI automation across multi-team workflows. The customer list already includes Zurich Insurance, JLL, Commerzbank, Volkswagen, and logistics group Fiege.

Use of Proceeds and Vision

The capital will accelerate development of the Context Graph and Chief of Staff agent, expand enterprise sales across the DACH region and broader Europe, and grow the engineering team. Interloom's positioning is that it wants to be the standard infrastructure layer for enterprise AI automation, the operating system for organizational knowledge that AI agents need to function.

Market Context

Gartner projects the AI agent market will exceed $50B by 2030. But the bottleneck isn't building agents. It's giving them enough context to be useful. Most enterprises are discovering this the hard way after failed pilots. Interloom is arriving at exactly the right moment: companies have budget for AI automation, they've tried generic solutions that didn't work, and they're now looking for the missing piece. Organizational context is that piece.

Lessons For Founders

• Solve integration, not just intelligence. Both Parallel and Interloom succeed not because their AI is smarter, but because they've found ways around the barriers that block deployment. Parallel bypasses API integration entirely. Interloom fills the knowledge gap that makes agents useful. The lesson: the best AI product in the world is worthless if it can't get into production.
• Build data flywheels from day one. Parallel's coding accuracy improves with every hospital deployment. Interloom's Context Graph gets better with every operational record ingested. Both companies designed their products so that usage directly improves the product, creating compounding advantages that late entrants can't shortcut.
• Target the "boring" workflows that eat budgets. Medical coding and enterprise knowledge management don't make headlines. But they represent billions in annual spend, and the incumbents are BPO firms and legacy software, not well-funded startups. Boring + expensive + underserved is a strong formula for venture-scale outcomes.
• Prior exits build trust in enterprise sales. Rydahl's Hublo gave Parallel instant credibility with hospital administrators. Jakobi's Boxplot exit to Hyperscience gave Interloom a head start with enterprise buyers. For founders targeting large organizations, a track record of building and shipping real products is worth more than a Stanford pedigree.